Análisis de la acción Moderna Inc (MRNA)MRNAModerna Inc

Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Moderna Inc is currently not a strong buy at $218.01 due to mixed analyst ratings and significant recent volatility. The RSI is at 55.19, indicating a neutral momentum, while the stock has experienced a 3.11% decline over the past five days. The forward P/E ratio is 23.04, suggesting that the stock may be overvalued compared to earnings expectations. The main risk is the hedge fund selling activity, which has increased by 437.15% over the last quarter, indicating a bearish sentiment among institutional investors.